Stage IV Prostate Cancer Clinical Trial
Official title:
A Comparison of Tangerine and Red Tomato Juice in Men With Prostate Cancer: A Pilot Study
This randomized pilot clinical trial compares tangerine and red tomato juice in treating patients with prostate cancer undergoing surgery. A diet high in lycopene, a substance found in tomatoes, may help prevent normal cells from transforming into cancer cells in patients with prostate cancer.
PRIMARY OBJECTIVES:
I. To conduct a randomized, three-arm pilot clinical trial to determine compliance and safety
of daily consumption of tangerine tomato juice or red tomato juice.
SECONDARY OBJECTIVES:
I. To quantify total carotenoids, total lycopene (LYC), cis-LYC, trans-LYC, phytoene,
phytofluene, and lycopene metabolites in plasma and prostate tissue in the three groups of
men.
II. To evaluate serum biomarkers related to prostate carcinogenesis, including those
previously impacted by tomato phytochemicals (testosterone, sex hormone-binding protein
[SHBP], insulin-like growth factor [IGF]-I, IGF-binding protein [BP]3, vascular endothelial
growth factor [VEGF], and a panel of anti-inflammatory cytokines) by validated assays.
III. To evaluate molecular signatures using the 200 gene quantitative Nano-string nCounter
code set (selected genes known to be impacted by dietary components, genes impacted by common
prostate genetic and epigenetic damage, and those regulated by testosterone) and
micro-ribonucleic acid (RNA) nCounter code set.
IV. To plot the distribution of carotenoid metabolites across the matrix versus the
epithelium and cancer versus non-cancer areas of the prostate using matrix-assisted laser
desorption ionization (MALDI) imaging of a limited number of samples.
OUTLINE: Patients are randomized to 1 of 3 treatment groups.
GROUP I: Patients consume no tomato juice.
GROUP II: Patients consume two cans of tangerine tomato juice daily until their scheduled
surgery (approximately 4 weeks).
GROUP III: Patients consume two cans of red tomato juice daily until their scheduled surgery
(approximately 4 weeks).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02491411 -
Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
|
N/A | |
Active, not recruiting |
NCT01685125 -
Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
|
Phase 2 | |
Completed |
NCT00936975 -
Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases
|
Phase 2 | |
Completed |
NCT00087139 -
Ixabepilone in Treating Patients With Metastatic Prostate Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03511196 -
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
|
Early Phase 1 | |
Completed |
NCT01881867 -
CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 | |
Completed |
NCT01385059 -
Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer
|
Phase 2 | |
Terminated |
NCT01866423 -
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02807805 -
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
|
Phase 2 | |
Completed |
NCT01468532 -
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01026623 -
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01682941 -
Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen
|
N/A | |
Terminated |
NCT00536991 -
Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00074022 -
GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03707184 -
Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone
|
Phase 2 | |
Withdrawn |
NCT00003534 -
Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT04113096 -
Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer
|
Early Phase 1 | |
Active, not recruiting |
NCT03344211 -
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
|
Phase 2 | |
Terminated |
NCT02985021 -
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
|
Phase 2 | |
Recruiting |
NCT02615223 -
Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer
|
N/A |